ERF deletion rescues RAS deficiency in mouse embryonic stem cells

  1. Oscar Fernandez-Capetillo1,5
  1. 1Genomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain;
  2. 2Experimental Oncology Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain;
  3. 3Transgenic Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain;
  4. 4Genomics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain;
  5. 5Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden
  1. Corresponding authors: ofernandez{at}cnio.es, sruizm{at}cnio.es

Abstract

MEK inhibition in combination with a glycogen synthase kinase-3β (GSK3β) inhibitor, referred as the 2i condition, favors pluripotency in embryonic stem cells (ESCs). However, the mechanisms by which the 2i condition limits ESC differentiation and whether RAS proteins are involved in this phenomenon remain poorly understood. Here we show that RAS nullyzygosity reduces the growth of mouse ESCs (mESCs) and prohibits their differentiation. Upon RAS deficiency or MEK inhibition, ERF (E twenty-six 2 [Ets2]-repressive factor), a transcriptional repressor from the ETS domain family, translocates to the nucleus, where it binds to the enhancers of pluripotency factors and key RAS targets. Remarkably, deletion of Erf rescues the proliferative defects of RAS-devoid mESCs and restores their capacity to differentiate. Furthermore, we show that Erf loss enables the development of RAS nullyzygous teratomas. In summary, this work reveals an essential role for RAS proteins in pluripotency and identifies ERF as a key mediator of the response to RAS/MEK/ERK inhibition in mESCs.

Keywords

Footnotes

  • Received November 27, 2017.
  • Accepted March 12, 2018.

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents

Life Science Alliance